Keywords magnetic resonance imaging - breast cancer - synchronous masses - satellite masses
- multifocal - multicentric
Introduction
Magnetic resonance imaging (MRI) of the breasts is a useful imaging modality for detection
and characterization of breast lesions. Indications for breast MRI include screening
of high-risk patients (e.g., patients with BRCA 1 gene), determination of extent of disease and presence of multifocality and multicentricity,
assessment of neoadjuvant chemotherapy response, localization of occult primary tumor
in patients presenting with histologically proven breast cancer metastasis and in
evaluation of breast implant. MRI breast must be evaluated together with clinical
history, physical examination, and conventional imaging including mammography and
ultrasound.[1 ]
[2 ]
Breast conservation surgery (BCS) requires precise assessment of extent of disease
to avoid inadequate surgical management. MRI is more sensitive than combined sonomammography
in the detection of multiple cancer foci especially in heterogeneous and extremely
dense breasts and in patients with ductal carcinoma in situ (DCIS), invasive lobular
carcinoma and Paget's disease.[3 ]
[4 ] MRI can detect clinically and mammographically occult cancers with sensitivity ranging
from 94 to 100% for invasive carcinoma and from 40 to 100% for DCIS.[5 ] However, limitations include low specificity, ranging from 40 to 80%, a large number
of false-positive findings and difficulty in managing incidentally detected lesions.[6 ]
The aim of this study was to determine the diagnostic accuracy of MRI in classifying
incidental breast masses in biopsy-proven breast cancer patients as benign or malignant
masses and correlation with histopathological findings of ultrasound-guided biopsy/FNA
and assessing the impact of these findings on surgical management of these patients,
i.e., breast conservation therapy versus mastectomy/wider excision. We also wanted
to find the incidence of additional satellite masses picked up during second-look
ultrasound after MRI that were not documented on initial ultrasound.
Materials and Methods
Our hospital institutional review board approved the retrospective data collection
for this study and granted waiver for informed consent for all patients (EX-05–08–19–01).
The Hospital Information System (HIS) was reached for records of breast cancer patients
undergoing breast MRI from August 01, 2016, to July 31, 2019. In our hospital, MRI
breast is performed in conjunction to conventional sonomammography for patients with
dense breast, invasive lobular carcinoma, suspected multifocal (MF)/multicentric (MC)
disease, young age (less than 30 years) and Paget's disease. We included all patients
with satellite masses seen on baseline MRI for which pathological diagnosis was available.
Patients with no evidence of satellite lesions on MRI or for which pathological diagnosis
was not available were excluded.
Dynamic contrast-enhanced MRI study of breasts was performed with MAGNETOM Vida 3 Tesla
(Siemens) and Ingenia 1.5 Tesla (Philips) using a dedicated breast surface coil and
the patient in prone position. Noncontrast axial T1, T2, short tau inversion recovery
(STIR) and dynamic post-contrast axial and sagittal T1 fat saturation, and subtraction
images were acquired after IV administration of contrast medium (0.1 mmol/kg gadovist).
Images were reviewed by four radiologists, one had fellowship training in breast imaging
followed by 2 years of experience in breast imaging. The other consultant radiologists
had 7 to 15 years of experience in breast imaging.
The following data were obtained from HIS: age, sex, laterality, primary diagnosis,
location of satellite masses and their distance from main mass, MRI features of satellite
masses, histopathology/cytology of satellite masses, documentation of additional masses
on second-look ultrasound, and type of surgery performed.
Satellite masses were evaluated for morphology and enhancement patterns according
to American College of Radiology (ACR) BI-RADS Atlas fifth edition guidelines.[7 ] MRI features of shape (round, oval or irregular), margin (circumscribed, not circumscribed
[spiculated or irregular]) and T2-weighted image (T2WI) signals (low, intermediate,
and high) were documented. Internal enhancement patterns were also assessed (homogeneous,
heterogeneous, rim enhancement, dark internal septations).[7 ] Qualitative assessment of lesion enhancement was done dynamically by plotting signal
intensity values after contrast injection. This comprises an initial phase within
the first 2 minutes (slow, medium, or fast) and delayed phase after 2 minutes (persistent,
plateau, or washout). Type I curve is a pattern of progressive enhancement, type II
curve has a rapid initial rise in the signal intensity followed by plateau pattern
and type III involves an initial fast increase in enhancement followed by washout
pattern.[7 ]
[8 ] The presence of diffusion restriction (present or absent) was also noted. The satellite
masses with at least one malignant feature were categorized as malignant, while masses
with all benign features were classed as probably benign.
Typical benign features include smooth margins, lobulated shape with non-enhancing
internal septa, and homogenous enhancement with type I kinetic curve. Criteria for
malignant features include irregular mass with non-circumscribed margins (irregular
or spiculated), T2WI hypointense signal, showing heterogenous or rim-like enhancement
or enhancing septations and diffusion restriction. Both type II and III enhancement
curves were considered suggestive of malignancy.[2 ]
[8 ] This was compared with results of histopathological examination. The location of
the satellite mass (same or different quadrant in same breast or in opposite breast)
and type of surgery were also documented.
Results
From August 01, 2016, to July 31, 2019, MRI breast was performed for 400 patients.
Out of these 400 patients, 115 patients had multiple masses on base-line MRI. Histopathological
diagnosis was available for 73 patients, 42 patients had single-satellite lesion,
18 patients had two satellite masses, 5 patients had three, and more than three synchronous
masses were noted in 8 patients. A total of 93 satellite masses were evaluated. Masses
without histopathological correlation were excluded. All patients were females (mean
age: 45.6 years; range: 22–81 years). Based on the distance from the main mass and
clock location, 38 masses were noted in the same quadrant, 26 in the opposite quadrant,
and 29 masses were seen in the opposite breast. There was evidence of additional masses
on MRI in 21 patients, which were subsequently noted on second-look ultrasound.
[Fig. 1 ] shows pathological outcome satellite masses according to the MRI feature of shape
of the lesion. Most of the benign masses were round or oval in shape (14 masses; 43.75%
and 12 masses; 37.5%, respectively), while 41 out of 61 malignant masses had an irregular
shape (67.2%). [Fig. 2 ] shows that most of the benign masses had circumscribed margins (25 masses; 78.1%);
while nearly two-thirds (62.3%) of malignant masses had non-circumscribed margins
with spiculated margins noted in 20 masses, and irregular margins in 18 masses. Nonmass
enhancement (NME) was observed in three lesions with malignant outcome (ILCa) of two
areas of segmental heterogeneous enhancement in the same patient; while focal heterogeneous
NME turned out benign (stromal fibrosis). Also, 78.1% of benign masses were bright
on T2WI (25 masses). Of malignant masses, only 10 masses were hypointense on T2WI
(16.39%), 11 were T2WI intermediate (18%), and 65.56% (40 masses) were hyperintense
([Fig. 3 ]). Three quarter of benign masses (24 masses) did not restrict diffusion, while diffusion
restriction was appreciated in most of malignant masses (49 masses; 80.3%) ([Fig. 4 ]).
Fig. 1 MRI features of shape of satellite masses.
Fig. 2 MRI features of margins of satellite masses.
Fig. 3 T2WI signal intensity of satellite masses.
Fig. 4 Diffusion-weighted imaging of satellite masses.
Most of benign masses showed homogenous internal enhancement pattern (21 masses; 65.63%),
and showed type I enhancement curve (21 masses; 65.63%). Thirty-six malignant masses
had heterogeneous internal enhancement pattern (59%) and 18 masses (29.5%) had homogenous
enhancement pattern. Thirty-three masses showed type I enhancement curve (54.1%),
19 masses showed type II (31.15%), while type III curve was seen in only 9 masses
(14.75%) ([Figs. 5 ] and [6 ]).
Fig. 5 Internal enhancement pattern of satellite masses.
Fig. 6 Enhancement kinetic curves of satellite masses.
Out of 72 masses categorized as malignant on MRI, 58 showed malignant pathological
outcome, while out of 21 masses characterized as benign on MRI, 18 turned out to be
benign on histopathology. Pearson's chi-square test was used to find an association
between MRI findings and final histopathology results. A statistically significant
association was found between MRI features and pathological outcome of satellite masses
(p = 0.001). The sensitivity, specificity, positive and negative predictive values,
and accuracy were 95%, 56%, 80.56%, 85.7% and 81.7%, respectively.
[Fig. 7 ] shows different types for surgeries performed for patients. Most of patients underwent
modified radical mastectomy (MRM)/mastectomy (42 patients). Fifteen patients had a
single malignant satellite lesion in the same quadrant, 13 patients had a single satellite
mass in a different quadrant, and 5 patients had two malignant satellite masses. This
group also included nine patients with a benign satellite mass in the same or contralateral
breast. BCS confined to a single presenting malignant mass was done for five patients.
The satellite masses in these patients turned out benign on final histopathology/cytology.
Extended resection with wire localization of malignant satellite lesion was done for
14 patients. The satellite lesions were located in the same quadrant of primary malignant
mass in eight patients, while in different quadrant in six patients. Bilateral BCS
was done for five patients due to malignant masses in the opposite breast. MRM/mastectomy
with contralateral BCS was done for four patients. Two patients underwent bilateral
MRM due to extensive DCIS in one patient, while the second patient had bilateral multicentric
ILC. One patient was lost to follow-up.
Fig. 7 Types of breast surgeries offered to breast cancer patients.
Discussion
Breast cancer treatment has been revolutionized since the last few decades, with BCS
being considered the preferred therapeutic option.[4 ] BCS requires accurate pre-surgical staging of breast cancer with precise detection
of multifocal (MF)/multicentric (MC) and contralateral disease, assessment of patients'
risk factors, and multidisciplinary team (MDT) discussion. Multiple tumors are defined
by the presence of synchronous invasive tumors in the same breast and are further
categorized as MF when there is more than one distinct tumor within the same quadrant
of the breast and MC when multiple cancers develop in different quadrants of the breast.[9 ] MF/MC breast cancers have been reported with an incidence of 40 to 70% in serial
sectioning of mastectomy specimens.[10 ]
[11 ] The incidence of contralateral synchronous tumors ranges from 0.3 to 3%.[12 ]
Breast MRI is the most sensitive modality for the detection of additional satellite
masses that are not detectable with conventional imaging techniques, particularly
in scattered fibroglandular or heterogeneously and extremely dense breasts with sensitivity
ranging from 94 to 100% for invasive carcinoma and from 40 to 100% for DCIS.[3 ]
[5 ] It has been reported in earlier studies that MRI has increased sensitivity (81 to
89%) for correct detection of MF/MC cancer in comparison with mammography alone (48
to 72%) or combined sonomammography (26 to 63%).[3 ] An MRI-detected lesion is defined as an enhancing lesion that is not considered
as normal breast parenchyma by breast radiologists and was not detected at conventional
imaging or physical examination. An MRI-detected lesion has been documented in 11
to 29% of patients in earlier published studies. This variation is attributed to differences
in patient population and definition criteria.[13 ] Our study showed similar incidence of MRI-detected lesion of 28.8%. The most important
disadvantage of breast MRI is low specificity (ranging from 40 to 80%), which means
that new MRI-detected lesions must always be biopsied before changing therapy.[6 ] MRI-guided biopsy and needle localization can be performed, but these methods are
not widely available and are both costly and time consuming. Other limitations include
contrast administration and difficult approach to posteriorly located lesions.[5 ]
[14 ] Second-look ultrasound refers to ultrasound examination to locate additional lesions
noted on MRI. US-guided biopsy is preferable to MRI-guided biopsy due to easy accessibility,
less cost, real-time visualization of lesions, and less patient discomfort.[14 ]
The MRI features of margins of a mass are most important predictive features of malignant
potential. Features suggestive of benign entity are circumscribed masses with smooth
margins (NPV 95%). Masses with irregular or spiculated margins are highly suggestive
of malignancy (84–91%).[8 ]
[15 ] Our study showed similar results with most of the benign masses having a lobulated
shape with circumscribed margins, while the malignant masses were irregular in shape
with non-circumscribed margins. T2 signal hyperintensity in the enhancing part of
the circumscribed mass is highly suggestive of benign etiology. A lobulated mass with
little or no enhancement is likely benign (NPV 100%).[8 ] Breast cancers usually appear iso- to hypointense on T2WI (87%); however, T2WI hyperintense
signal in irregular or spiculated masses should not be considered a reliable sign
of benign histopathology.[2 ]
[8 ] In contrast to this, most of malignant masses did not appear hypointense on T2WI
in our study. Rim-like enhancement in an uncommon feature; however, when present it
is highly suggestive of cancer (PPV 84%).[8 ]
[15 ] Heterogenous internal enhancement pattern and enhancing internal septations are
also suspicious for malignancy. Regional nonmass enhancement with a stippled pattern
is noted in both benign and malignant conditions. Clumped, heterogenous, and homogenous
nonmass enhancement is usually associated with an increased malignancy risk.[8 ] Type I enhancement curve is usually associated with benign findings with 9% risk
of malignancy. The sensitivity and specificity for predicting benign nature were 52.2%
and 71%, respectively. Type II curve has 42.6% sensitivity and 75% specificity for
the detection of malignancy. Type III curve is usually not observed in benign masses
(specificity of 90.4%) but has sensitivity of 20.5%. Both type II and III curves should
be considered suspicious for malignancy. Nearly half of malignant masses showed type
I enhancement curve in our study. As there is an overlap in enhancement characteristics
of benign and malignant masses, reliance on kinetic curve alone should not be done,
rather both morphological and kinetic features should be considered during MRI interpretation.[8 ]
Diffusion restriction was noted in a significant number of satellite masses in this
study (sensitivity 85.96%). It has been shown in earlier reported studies that DWI
is a useful additional tool for breast cancer diagnosis and ADC values are significantly
lower in malignant masses as compared with benign masses or normal breast tissue.[16 ] The reported sensitivity and specificity in diagnosing malignant masses ranges from
62.5 to 92.8% and 45.8 to 96.7%, respectively.[17 ] Cai et al demonstrated a marked improvement in the diagnostic performance and specificity
of breast MRI in characterization of breast lesions by combining DWI with Dynamic
Contrast Enhanced (DCE) MRI.[18 ]
Sensitivity of MRI in the detection of additional tumor foci leading to a modification
in treatment plan has been demonstrated in several studies.[19 ] Detection of additional tumor foci results in the change in the type of surgery,
such as, extended resection, quadrantectomy, or mastectomy, or bilateral surgery due
to synchronous MF/bilateral tumors.[20 ]
[21 ] In our hospital too, the final treatment plan is discussed in MDT after the review
of multimodality imaging findings, histopathological diagnosis, hormonal receptor
status, axillary and distal metastatic work up results.
There are several limitations in our study. First, it was a retrospective single-center
study. Second, we evaluated satellite masses in known breast cancer patients, so our
results can be different from masses seen in the screening population. Third, we included
only the masses with histopathological diagnosis and excluded a large number, for
which the pathological diagnosis was not available. Nevertheless, this study explores
different aspects of MRI breast and will surely lead to further prospective studies.
Conclusion
Breast MRI is the most sensitive imaging modality in the accurate assessment of disease
extent and the presence of multiple tumor foci in breast cancer patients. However,
the major disadvantage is its low specificity. Therefore, biopsy should be performed
to ascertain the most appropriate treatment plan.
